Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Filter articles using the following links
Financial press releases
Events & presentations
Year
All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
04 February 2019
GenSight Biologics Updates its 2019 Financial Calendar
28 Apr 2019 - 02 May 2019
ARVO Annual Meeting, Vancouver, BC, Canada
25 Mar 2019 - 27 Mar 2019
BioEurope Spring, Vienna, Austria
23 January 2019
GenSight Biologics Announces its 2019 Financial Calendar
23 January 2019
GenSight Biologics Reports its Cash Position as of December 31, 2018
12 December 2018
GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
16 Mar 2019 - 21 Mar 2019
45th NANOS Annual Meeting, Las Vegas, Nevada, US
10 Jan 2019 - 11 Jan 2019
Oddo BHF Forum, Lyon, France
07 Jan 2019 - 10 Jan 2019
37th Annual J.P. Morgan Healthcare Conference, San Francisco (CA), USA
06 Nov 2018 - 08 Nov 2018
World Orphan Drug Congress Europe, Barcelona, Spain
View previous 9 articles
1
…
22
23
24
25
26
27
28
29
30
31
32
…
41
View next 9 articles
Go back to the page of the page
